Side-by-side · Research reference

GHRP-6vsPancragen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED10/36 cited

BAnimal-StrongHUMAN-REVIEWED23/39 cited

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

01Mechanism of Action

Parameter

GHRP-6

Pancragen

Primary target

Ghrelin receptor (GHS-R1a)Bowers 1990

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Downstream effect

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Feedback intact?

—

Yes — preserves physiological glucose-insulin response

Origin

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Antibody development

—

02Dosage Protocols

Parameter

GHRP-6

Pancragen

Standard dose

100–200 mcg per injectionBowers 1990

—

Frequency

1–3× per day

Once daily for 10 daysGoncharova 2014

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceBowers 1990

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Duration

8–12 weeks on / 4 off

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-meal preferred for appetite support

—

Half-life

~15 minMalagón 1999

—

Primate dose (rhesus macaque)

—

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

Route

—

IntramuscularGoncharova 2015

Treatment cycle

—

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

Diabetes model

—

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

04Side Effects & Safety

Parameter

GHRP-6

Pancragen

Hunger

Pronounced — defining feature vs ipamorelin

—

Cortisol elevation

Mild

—

Prolactin elevation

Mild

—

Injection site reaction

Mild

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Reported adverse events

—

None documented in primate studies

Tolerability

—

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

Human safety data

—

No published human trials; clinical use limited to Russian gerontology protocols

Absolute Contraindications

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Pancragen

—

Relative Contraindications

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

05Administration Protocol

Parameter

GHRP-6

Pancragen

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

2. Injection site

SQ — abdomen. Rotate sites.

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

3. Timing

Pre-meal for appetite support; pre-sleep for GH alignment.

No specific timing constraints documented. Administered once daily in primate protocols.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

5. Needle

29–31G, 4–8 mm insulin syringe.

—